Updated: Amgen spotlights new efficacy, safety data of mid-phase tarlatamab trial in hard-to-treat cancer: #ESMO23

Reynald Castañeda

Deputy Editor

MADRID — Amgen’s Phase II trial of its bispecific T cell engager tarlatamab showed a response rate of 40% of patients with small cell lung cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Amgen spotlights new efficacy, safety data of mid-phase tarlatamab trial in hard-to-treat cancer: #ESMO23

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Breaking down silos with a new quantitative approach to drug development

Up­dat­ed: Am­gen spot­lights new ef­fi­ca­cy, safe­ty da­ta of mid-phase tar­latam­ab tri­al in hard-to-treat can­cer: #ES­MO23

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

Sanofi's BTK in­hibitor again slows MS pro­gres­sion, but liv­er en­zymes con­tin­ue to be tricky

Lex­i­con's pres­i­dent to step down as de­ci­sion date looms; Sarep­ta wel­comes Lil­ly, GSK vet to board

Gilead­'s Kite un­cou­ples from Fo­s­un in Chi­na as Yescar­ta faces cov­er­age ob­sta­cles

Ali­gos’ tri­al for oral MASH treat­ment suc­ceeds, but place­bo group shows odd trend

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

Updated: Amgen spotlights new efficacy, safety data of mid-phase tarlatamab trial in hard-to-treat cancer: #ESMO23

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Breaking down silos with a new quantitative approach to drug development